文献速递临床试验与 GCP流行病学与生物统计基础与转化研究

NC NEXUS研究:评估父母对新生儿二代测序筛查决策的随机对照试验方案

Evaluating parents' decisions about next-generation sequencing for their child in the NC NEXUS (North Carolina Newborn Exome Sequencing for Universal Screening) study: a randomized controlled trial protocol.
PubMed 文献 · Trials · 2018-06-28

NC NEXUS研究旨在评估二代测序用于新生儿筛查的技术可能性和局限,并制定信息传达框架与临床整合最佳实践。研究纳入健康队列和经传统新生儿筛查确诊的患病队列,各目标200名儿童,采用基于年龄的指标分类数据,并使用在线决策辅助工具引导父母决策。主要结局包括NGS-NBS灵敏度评估、决策后悔和父母决策,以及随机分组父母对额外发现的决策。

要点

  • 评估NGS-NBS灵敏度、父母决策后悔及决策行为是主要结局。
  • 父母随机分为决策臂与对照臂(2:1),决策臂使用决策辅助工具选择额外结果。
  • 研究纳入健康儿童和经传统新生儿筛查确诊的患病儿童两个队列。

核心结论

  • NC NEXUS将采用严谨的跨学科方法收集丰富数据,为政策、实践和未来研究提供依据。

研究设计与样本

  • 随机对照试验方案,招募产前诊所的健康儿童父母和儿科诊所的患病儿童父母,每个队列目标200名儿童。

主要发现

  • 尚未报告研究结果,方案描述了三阶段流程和结局评估计划。

关键数值与推荐

  • 主要结局包括NGS-NBS灵敏度评估、决策后悔和父母关于NGS-NBS的决策,以及随机分组父母对额外发现的决策。
  • 同意NGS-NBS的父母按2:1随机分配至决策臂或对照臂,决策臂使用第二决策辅助工具决定额外结果。
  • 在线问卷在最多五个时间点进行。

临床怎么用

  • 研究结果预期为将NGS-NBS整合入临床实践提供最佳实践依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Using next-generation sequencing (NGS) in newborn screening (NBS) could expand the number of genetic conditions detected pre-symptomatically, simultaneously challenging current precedents, raising ethical concerns, and extending the role of parental decision-making in NBS. The NC NEXUS (Newborn Exome Sequencing for Universal Screening) study seeks to assess the technical possibilities and limitations of NGS-NBS, devise and evaluate a framework to convey various types of genetic information, and develop best practices for incorporating NGS-NBS into clinical care. The study is enrolling both a healthy cohort and a cohort diagnosed with known disorders identified through recent routine NBS. It uses a novel age-based metric to categorize a priori the large amount of data generated by NGS-NBS and interactive online decision aids to guide parental decision-making. Primary outcomes include: (1) assessment of NGS-NBS sensitivity, (2) decision regret, and (3) parental decision-making about NGS-NBS, and, for parents randomized to have the option of requesting them, additional findings (diagnosed and healthy cohorts). Secondary outcomes assess parents' reactions to the study and to decision-making. METHODS/DESIGN: Participants are parents and children in a well-child cohort recruited from a prenatal clinic and a diagnosed cohort recruited from pediatric clinics that treat children with disorders diagnosed through traditional NBS (goal of 200 children in each cohort). In phase 1, all parent participants use an online decision aid to decide whether to accept NGS-NBS for their child and provide consent for NGS-NBS. In phase 2, parents who consent to NGS-NBS are randomized to a decision arm or control arm (2:1 allocation) and learn their child's NGS-NBS results, which include conditions from standard (non-NGS) NBS plus other highly actionable childhood-onset conditions. Parents in the decision arm use a second decision aid to make decisions about additional results from their child's sequencing. In phase 3, decision arm participants learn additional results they have requested. Online questionnaires are administered at up to five time points. DISCUSSION: NC NEXUS will use a rigorous interdisciplinary approach designed to collect rich data to inform policy, practice, and future research. TRIAL REGISTRATION: clinicaltrials.gov, NCT02826694 . Registered on 11 July, 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Milko LV, Rini C, Lewis MA, et al. Evaluating parents' decisions about next-generation sequencing for their child in the NC NEXUS (North Carolina Newborn Exome Sequencing for Universal Screening) study: a randomized controlled trial protocol. Trials. 2018. PMID: 29950170. doi:10.1186/s13063-018-2686-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。